Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
- 1 September 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in CNS Drugs
- Vol. 26 (9), 733-759
- https://doi.org/10.2165/11634500-000000000-00000
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Antipsychotic drugs and obesityTrends in Molecular Medicine, 2011
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJournal of Psychopharmacology, 2010
- A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in SchizophreniaNeuropsychopharmacology, 2010
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia PatientsNeuropsychopharmacology, 2010
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-AnalysisNeuropsychopharmacology, 2010
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Schizophrenia Research, 2008
- Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysisSchizophrenia Research, 2007
- Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinaseProceedings of the National Academy of Sciences of the United States of America, 2007